Granulators are high speed rotor mills designed to convert a particle powder into sizeable granules. Granulation is a process of binding one or two materials together and making larger particles by using binding agents such as sugars and natural binders or synthetic polymers. Granulation is performed to improve flow properties of powdered active ingredients, which, in turn eases compression during tablet manufacturing. Also, it prevents segregation of the powdered substance. Granulation is performed by two methods, wet granulation and dry granulation. The choice of method depends on characteristics of powder and objective of tablet manufacturing. It refers to the process of size enlargement of pharmaceutical ingredients to prevent segregation of constituents in the powder mix. Granulation is commonly used for production of oral drug formulations such as tablets, pills, and capsules.

Furthermore, several pharmaceutical manufacturing companies are exploring technical solutions that can increase quality of drug, process throughput, reduce costs of manufacturing, and increase yield. One of the most promising solutions being studied and implemented is continuous manufacturing (CM). Continuous granulation is performed to continuously manufacture APIs and excipients.  The process of continuous manufacturing is gaining momentum in the pharmaceutical industry owing to increasing demand for faster product development, reduced costs of manufacturing, and higher manufacturing flexibility. The integration of continuous manufacturing process in the pharmaceuticals manufacturing industry has significantly increased efficiency of API and excipient manufacturers.

Market Dynamics

The pharmaceutical companies are focusing on expansion of their production facilities which would create additional demand for granulators used for producing drugs and for R&D activities. The increasing investments in production facilities by key players attributed to the growth of global pharmaceutical granulators market. For instance in September 2017, Fresenius Kabi announced an investment of US$ 250 million to establish a pharmaceutical plant in Illinois, U.S. for aseptic manufacturing of pharmaceutical drugs. Similarly, according to a survey report published by the USFDA in 2016, the top 15 pharmaceutical companies in the U.S. invested around 20.5% of their pharmaceutical sales in research and development of new drugs. Such strategies adopted by key players is projected to drive demand for pharmaceutical granulators.

Furthermore, technological innovations in development of drugs is another factor driving the growth of this market. For instance, in July 2017, Wittmann Battenfeld, Inc. introduced a new G-Max 23 granulator, which is a flexible, custom-made granulator that consumes less energy and delivers high performance. Additionally, in 2015, the Bosch GmBH, a Germany-based company developed a new granulation unit, Granulean, which is a novel pharmaceutical granulator that collectively carries out the process of mixing, granulating, and drying of the pharmaceutical granules. The launch of innovative and technologically advanced products is expected to drive growth of this market during the forecast period.         

Key features of the study

• This report provides in-depth analysis of the market, global pharmaceutical granulators market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2019-2027, considering 2018 as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global pharmaceutical granulators market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies.
• Key players covered as a part of this study include L.B. Bohle, Alexanderwerk, GEA Group Aktiengesellschaft, Frewitt S.A., LINXIS Group, Spraying Systems Co., Syntegon Technology GmbH, Romaco Group, Gebrüder Lödige Maschinenbau GmbH, and Glatt GmbH.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, market expansions, and marketing tactics.
• The global pharmaceutical granulators market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of reprocessed medical devices, research and consulting firms, new entrants, and financial analysts.

Market Segmentation

• By Product Type
  • Single Pot Granulators
  • High Sheer Granulators
  • Fluid Bed Granulators
  • Rapid Mixer Granulators
  • Oscillating Granulators
  • Others
• By Granulation Mechanism
  • Dry Granulators
  • Wet Granulators
  • Mixed Granulators
• By End User
  • Pharmaceutical Manufacturing Companies
  • Contract Manufacturing Organizations
  • Research Institutes
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa